On Biologics for Psoriatic Arthritis: Blood Tests, Vaccination Review and Infection Checks

The letter arrives a week after the rheumatology appointment, and it is longer than expected. A blood form with several boxes ticked. A chest X-ray slot. A note asking about a childhood vaccine card nobody has seen in decades. For someone who walked out of clinic relieved that a biologic had finally been offered for their psoriatic arthritis, the paperwork can feel like a second hurdle before the first one has been cleared.

That hurdle has a purpose. Psoriatic arthritis biologics monitoring exists because these medicines work by quieting a specific part of the immune system, and the same mechanism that calms swollen joints and flaking skin can let dormant infections wake up or new ones take hold more easily.

This explainer walks through what those checks are, why each one is there, how the first months usually unfold, and which signs should prompt a phone call rather than a wait for the next appointment. None of it replaces your own team’s plan; it should make that plan easier to follow.

What does psoriatic arthritis biologics monitoring actually involve?

Strip away the jargon and the monitoring plan has three jobs: make sure nothing is hiding that the medicine could make worse, build a baseline so later changes can be spotted, and keep watch once treatment is under way.

A biologic is a medicine made from living cells rather than mixed in a chemistry lab; in psoriatic arthritis it is usually an antibody designed to block one chemical messenger of inflammation. Because it is targeted, it does not suppress the whole immune system the way older steroid-based treatments can, but it does switch off a defense pathway that the body uses against certain infections. Monitoring is the trade-off that makes that targeted approach safe enough to use for years.

Before the first dose, most teams arrange blood tests that count blood cells and measure liver and kidney function, together with screening for tuberculosis and hepatitis B and C. Many also ask about past chickenpox or shingles, check a chest X-ray, and run through the vaccine history. Mayo Clinic notes that biologics can increase the risk of infections and that screening for tuberculosis is part of starting them.

Once treatment begins, the pattern shifts from screening to surveillance: repeat blood tests at intervals set by the prescriber, a check at each visit on infections, mouth ulcers, rashes or unexplained tiredness, and a periodic conversation about whether the drug is still doing its job. The NHS describes regular review and blood monitoring as standard for people on biological treatment for psoriatic arthritis.

Think of it less as a series of tests and more as a relationship with a schedule. The schedule changes with the drug chosen, with whether a conventional tablet such as methotrexate is taken alongside, and with your own history. What does not change is that the decisions sit with the team prescribing the medicine.

How do biologics work, and why does the mechanism shape the checks?

Inflammation in psoriatic arthritis is driven by cytokines, which are small signaling proteins that immune cells use to tell one another to attack. Three families matter most here: tumor necrosis factor (TNF), interleukin-17 and the interleukin-12/23 pathway. Each biologic class binds to one of these messengers, or to the receptor it docks onto, and blocks the signal.

That precision explains why the pre-treatment checklist looks the way it does. TNF is central to the body’s ability to wall off tuberculosis bacteria inside tiny clusters of immune cells called granulomas. Block TNF and a long-dormant infection can escape, which is why the tuberculosis test is the one check almost no prescriber will skip. The CDC describes tuberculosis that is present but inactive as latent infection, and recommends testing for people about to start medicines that weaken the immune response.

Hepatitis B behaves in a similar way. The virus can sit quietly in liver cells for decades after an infection the person may never have noticed. Several immune-modifying medicines have been linked with reactivation, so the screening blood test is drawn before treatment rather than after symptoms appear.

Interleukin-17 blockers raise a different question. That messenger helps defend the gut lining and the mouth against yeast, so people on these drugs are more often asked about thrush or recurrent fungal infections, and about any history of inflammatory bowel disease.

Cleveland Clinic summarizes the shared concern plainly: because biologics dampen part of the immune system, infection is the main risk the monitoring plan is built to catch. Knowing which pathway your medicine blocks turns an abstract list of tests into something you can reason about, which in turn makes it easier to notice the symptoms that matter for your particular drug.

Who is usually offered a biologic, and who is asked to wait?

Biologics are rarely the first medicine tried. In most guideline-based pathways, including the approach described by the NHS, people with psoriatic arthritis start with anti-inflammatory painkillers and then a conventional disease-modifying antirheumatic drug (DMARD), a tablet that slows the underlying disease rather than just easing pain. A biologic is usually considered when joints remain active despite one or more of those tablets, or when side effects make them impossible to continue.

Severity matters too. Teams weigh how many joints are swollen, whether tendons or the spine are involved, how much skin psoriasis is present, and how much daily life is affected. Someone with a few mildly stiff fingers and a different person with a swollen knee, inflamed heel tendons and extensive plaques may both have psoriatic arthritis but reach very different decisions.

The screening results themselves decide who is asked to pause. A positive tuberculosis test does not close the door; it usually means a course of preventive treatment for latent infection first, with the biologic delayed until that is safely established. Active hepatitis B typically means antiviral cover is arranged in advance. An active infection of any kind, from a chest infection to a leg ulcer that is not healing, is a reason to wait until it has cleared.

Some situations call for a careful choice of class rather than a delay. A history of multiple sclerosis or of heart failure shifts prescribers away from TNF blockers. Inflammatory bowel disease shifts them away from interleukin-17 blockers. Pregnancy, breastfeeding or plans for either prompt a specific conversation, because some biologics have more safety data in pregnancy than others.

None of these are rules a reader can apply alone. They are the kinds of factors a rheumatologist is balancing, and knowing them helps you understand why the questions in clinic are so detailed.

Which blood tests on biologics are done before the first dose?

The baseline blood draw is the quiet workhorse of the whole plan. It rarely finds anything alarming, yet without it a later change in a result has nothing to be compared against.

A full blood count measures red cells, white cells and platelets. White cells are the infection-fighting cells; a low count, called neutropenia when it affects the type that tackles bacteria, is uncommon on biologics but has been reported, and the baseline tells the team what normal looks like for you. Liver function tests check enzymes released when liver cells are stressed; they matter most when methotrexate is taken alongside, since that tablet is the more frequent cause of raised liver readings. Kidney tests, usually creatinine with an estimated filtration rate, confirm the kidneys are clearing waste normally, which also affects how safely some companion medicines can be used.

Inflammation markers come next. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) rise when the body is inflamed and are used as one yardstick of whether the disease is active and, later, whether the biologic is calming it. They are blunt tools, since a cold can raise them too, but tracked over months they add to the picture.

The infection screen is drawn from the same arm on the same day: tests for hepatitis B surface antigen and core antibody, hepatitis C antibody, and in many services HIV. Some teams add varicella (chickenpox) antibodies if there is no clear history of the illness, because the answer changes vaccine advice.

MedlinePlus lists blood testing among the routine investigations used in psoriatic arthritis care. Results are typically reviewed before the prescription is released, which is one reason the gap between the clinic decision and the first injection can feel longer than expected.

Why is a TB test before biologics treated as non-negotiable?

Of every check on the list, this is the one with the longest history and the clearest reasoning behind it.

Tuberculosis is caused by bacteria that the immune system often contains rather than destroys. According to the CDC, a person with latent tuberculosis infection has the bacteria in the body but no symptoms, cannot pass it on, and may feel entirely well for decades. The containment depends heavily on TNF and on the granulomas it helps maintain. When early TNF blockers reached clinics, cases of reactivated tuberculosis followed, and universal screening before treatment became standard.

Two tests are in common use. The tuberculin skin test involves a small injection under the skin of the forearm, read two to three days later for a raised bump; the CDC describes the return visit for reading as a required part of the test. The interferon-gamma release assay (IGRA) is a blood test that measures how immune cells react to tuberculosis proteins and needs only one visit. The CDC notes that the blood test is generally preferred for people who received the BCG vaccine in childhood, because that vaccine can cause a false positive on the skin test.

A positive result on either test means infection at some point, not necessarily active disease. The CDC states that further tests, usually a chest X-ray and sometimes a sputum sample, are needed to tell latent infection from tuberculosis disease. Latent infection is generally treated with a course of preventive medicine, and the biologic is started once that is under way, on a timeline the chest or infectious disease team agrees with the rheumatologist.

Screening is usually a one-time event, but the question does not disappear. Teams typically re-ask about new exposures, travel to high-incidence regions and a persistent cough at follow-up, and some repeat testing when the risk picture changes.

Hepatitis B, hepatitis C and HIV screening: what the results change

These viral screens sometimes surprise people who feel perfectly healthy, and the surprise is the point. Each of these infections can be silent for years, and each changes the plan in a specific way rather than simply ruling treatment out.

Hepatitis B is the most consequential. The screen usually includes two markers: surface antigen, which indicates current infection, and core antibody, which indicates past exposure even when the virus has apparently cleared. Immune-modifying treatment can allow a cleared infection to reactivate, so a positive core antibody typically triggers additional blood tests and a conversation with a liver specialist about whether antiviral protection should run alongside the biologic, together with closer liver monitoring. Current infection is managed in the same way with more urgency. Neither result necessarily prevents treatment.

Hepatitis C is a different story. Modern antiviral courses can clear the virus in most people who complete them, and a positive antibody test is more often a reason to arrange that treatment than to delay rheumatology care indefinitely. The sequencing is decided jointly.

HIV screening is included in many services because untreated HIV already weakens the immune system, and adding a biologic on top without knowing would be unwise. Well-controlled HIV on effective therapy is generally not a barrier, but it does shape the choice of biologic and the frequency of blood count checks.

Two points are worth holding onto. First, a positive result on any of these tests is confidential medical information handled like any other, and the team’s job is to adapt the plan, not to judge. Second, the vaccine review that follows often changes as a result: someone who tests negative for hepatitis B exposure may be offered the hepatitis B vaccine before starting, since it is a non-live vaccine that can be given safely alongside biologics.

Vaccines while on biologics: what gets reviewed before and after starting

The vaccine conversation tends to happen in the weeks before the first dose, and timing is the whole reason. Some vaccines work better before immune-modifying treatment begins, and one group of vaccines should generally not be given at all once it has.

That group is the live vaccines, which contain a weakened but living version of the germ. Measles-mumps-rubella, chickenpox, the older shingles vaccine that is no longer used in many countries, the nasal spray flu vaccine and yellow fever all fall into it. The CDC’s immunization guidance advises against live vaccines for people on medicines that substantially suppress immunity, because the weakened germ could, in theory, cause the illness it is meant to prevent. If any of these are needed, for example yellow fever before travel to a region that requires it, the discussion has to happen before treatment starts and often involves a deliberate gap before the first dose.

Non-live vaccines are a different matter and are generally encouraged. The CDC adult immunization schedule recommends yearly influenza vaccination for all adults, COVID-19 vaccination according to current guidance, and pneumococcal vaccination for adults with immunocompromising conditions, including those on immunosuppressive treatment. The recombinant shingles vaccine, which is non-live, is recommended by the CDC for adults aged 50 and over and for immunocompromised adults from age 19, a change that covers many people starting biologics.

Hepatitis B vaccination comes up for anyone without evidence of past infection or immunity, and the usual tetanus-containing boosters stay on their normal timetable.

One practical note: a biologic may blunt the immune response to a vaccine, which is why teams prefer to give what they can beforehand. It is not a reason to skip vaccines later; a partial response is still better than none. Household members can and should receive their own routine vaccines, including live ones, in almost all circumstances.

A summary table of the usual checks and when they tend to happen

The individual pieces make more sense laid side by side. The timing column describes common practice as outlined by the NHS, Mayo Clinic and CDC rather than a fixed rule; your own prescriber sets the actual intervals, and they often differ depending on the specific biologic and on whether a conventional DMARD is taken alongside.

Check	What it looks for	Usual timing	What a positive or abnormal result commonly changes
Full blood count	Low white cells, platelets or anemia	Before starting, then at intervals set by the prescriber	Repeat testing, review of companion medicines, occasionally a pause
Liver and kidney tests	Enzyme rises, reduced kidney filtration	Before starting, then alongside blood counts	Closer monitoring; most often prompts review of methotrexate rather than the biologic
Tuberculosis test (skin or IGRA) with chest X-ray	Latent or active tuberculosis	Before the first dose; re-asked about at follow-up	Preventive or full tuberculosis treatment first; biologic deferred until established
Hepatitis B and C, HIV	Current or past viral infection	Before the first dose	Specialist input, antiviral cover or treatment, closer liver tests
Vaccine review	Missing non-live vaccines; any live vaccines needed	Before starting, then updated yearly	Live vaccines given before treatment or avoided; non-live vaccines given as due
Infection and symptom review	Fever, cough, skin, mouth or urinary infections	Every visit and between visits by phone	Treatment of the infection; the biologic is often held until recovery
Skin check	Changes in moles or new skin lesions	At visits, especially with TNF blockers and prior skin cancer	Dermatology referral if anything looks suspicious

Reading down the final column shows the pattern: very few abnormal results end treatment outright. Most redirect it, delay it briefly, or add a safeguard. That is the reassuring message behind what can look like a daunting list.

What the first weeks and months on a biologic usually look like

Once the screening results are cleared, the rhythm of care changes from preparation to watchfulness, and most people find it less intrusive than they feared.

The first dose is often given in a clinic or infusion unit, or taught as a self-injection with a nurse watching. Reactions at the injection site, such as redness or a small itchy swelling, are the most common early complaint and usually settle within days. Infusion reactions during an intravenous dose are watched for on the day, which is why the first sessions can take longer than later ones.

Blood tests in the early phase are typically closer together than they will be later. Teams are looking for an unexpected drop in white cells, a rise in liver enzymes, or a new anemia, and they are looking early because that is when a problem, if it comes, is most likely to appear. As results stay stable, intervals usually lengthen.

Benefit does not arrive overnight. The NHS and Mayo Clinic both describe a review after the first months of treatment to judge whether the biologic is working, using joint counts, skin assessment, inflammation markers and how you feel day to day. Some people notice easier mornings within weeks; for others the change is gradual enough that it only becomes obvious when they realize a stair rail has gone unused. If there is no meaningful response by the review point, switching to a different class is a routine next step rather than a failure.

Through all of this, the infection conversation stays open. Most clinics ask you to phone before a dose if you have a fever, are taking antibiotics, or are about to have surgery, so that a dose can be held if needed. Keeping a simple note of any infections, however minor, makes those check-ins quicker and more useful.

Routine psoriatic arthritis biologics monitoring once treatment is established

After the first year the monitoring plan usually settles into something predictable, and its character shifts from catching early problems to confirming that nothing has drifted.

Blood tests continue, but the interval is set by the prescriber and depends heavily on what else is being taken. Biologics used alone tend to need less frequent blood work than biologics combined with methotrexate, where the tablet rather than the injection drives most of the liver and blood count monitoring. The NHS describes ongoing regular review for anyone on biological treatment, with the specifics agreed by the specialist team.

Each review visit covers a similar set of questions. Have there been infections, and how quickly did they clear? Any new rashes, mouth ulcers, unexplained weight loss, night sweats or persistent cough? Any new numbness or weakness, which teams on TNF blockers ask about because of a rare link with nerve inflammation? Any new or changing moles? These are not boxes to tick; a pattern of slow-healing minor infections is exactly the kind of signal that only shows up when someone asks consistently.

Disease activity is scored at most visits using swollen and tender joint counts, skin and nail assessment, and a measure of function. A rising score over two or three visits prompts a conversation about whether the biologic has lost effect, which can happen when the body develops antibodies against the medicine itself, and whether a switch is sensible.

Vaccines are updated yearly, with influenza and current COVID-19 guidance the regular items and pneumococcal or shingles vaccination addressed if not already given. The tuberculosis question is revisited whenever travel or contact history changes. Through it all, the two prompts that should never wait for the next scheduled visit are a significant infection and a planned operation, both covered in the sections that follow.

Biologic infection risk in psoriatic arthritis: what the evidence actually shows

It would be easy to leave this topic with either of two wrong impressions: that biologics are dangerous, or that the risk is trivial. The evidence supports neither.

Mayo Clinic, Cleveland Clinic and the NHS all describe an increased risk of infection as the principal safety concern with biologic medicines. The most frequent infections are ordinary ones, upper respiratory infections, urinary infections and skin infections, and most are treated the same way they would be in anyone else. The difference is that they may be more frequent and occasionally more stubborn, and a small number progress further than they otherwise would.

Serious infections, meaning those needing hospital care or intravenous antibiotics, are uncommon but not rare enough to ignore, and the risk is not evenly spread. It rises with older age, with diabetes, with lung disease, with steroid tablets taken alongside, and with a history of previous serious infection. A fit 35-year-old on a biologic alone and a 72-year-old with diabetes on a biologic plus prednisolone are in different risk brackets, and prescribers adjust how closely they watch accordingly.

The opportunistic infections that drive the screening program, tuberculosis and hepatitis B reactivation, have become far less common since universal pre-treatment testing was adopted, which is the clearest real-world evidence that the monitoring works.

Two further points deserve honesty. Active psoriatic arthritis itself, left untreated, carries its own health costs, including a higher burden of cardiovascular disease linked to chronic inflammation, so the comparison is never biologic versus perfect safety. And shingles deserves a specific mention: reactivation of the chickenpox virus is more common on several immune-modifying medicines, which is why the non-live shingles vaccine features so prominently in the pre-treatment review. If a painful one-sided rash appears, early treatment matters, and it is worth a same-day call.

Surgery, dental work, pregnancy and travel: when the monitoring conversation changes

Four everyday situations reliably prompt people to wonder whether their biologic should be paused, and all four are better raised with the team in advance than in a waiting room.

Planned surgery is the most common. Because biologics slow part of the healing and defense response, many surgical and rheumatology teams agree a short pause around an operation, timed to the particular drug’s duration of action, and restart once the wound is healing cleanly with no sign of infection. The exact gap differs between medicines and operations, so the decision is made case by case by the surgeon and rheumatologist together. The same logic applies to major dental procedures such as extractions or implants; routine cleaning and fillings generally need no change.

Pregnancy planning changes the picture in both directions. Uncontrolled psoriatic arthritis during pregnancy is itself unhelpful, and some biologic classes have reassuring safety data in pregnancy while others have less. A woman planning a pregnancy, or who discovers one, should contact her team early rather than stopping abruptly on her own; the choice of whether to continue, switch or pause is individual. Partners planning to father a child are generally advised that most biologics do not require a change, but the question is still worth asking.

Travel raises two issues: vaccines and exposure. Live travel vaccines such as yellow fever are generally avoided on treatment, so destinations that require them need discussion well ahead. Regions where tuberculosis is more common raise the exposure question, and teams may advise repeat testing on return if contact was likely. Carrying the medicine safely, keeping injectable biologics within their storage temperature range and having a letter describing the treatment are practical matters your clinic can help with.

Across all four situations the message is the same: the plan can flex, but only if the team knows in time.

What people often get wrong about monitoring on biologics

Misconceptions about these medicines travel fast, partly because the word “immunosuppression” carries a lot of weight. A few of the most common deserve correcting.

“If my blood tests are normal, I can skip the next ones.” Normal results are the reason intervals lengthen, not the reason testing stops. The early schedule is designed to find problems that are more likely at the start, and the later schedule is designed to catch slow drift. Both depend on actually attending.

“A positive tuberculosis test means I can never have a biologic.” Almost always untrue. The CDC distinguishes latent infection from active disease, and latent infection is treated preventively, after which the biologic is usually started. The test is a detour, not a dead end.

“I should avoid all vaccines now.” The reverse is closer to the truth. Non-live vaccines are recommended more strongly for people on biologics, not less, precisely because infections hit harder. Only live vaccines are the exception.

“I should stop the biologic as soon as I feel a cold coming.” Minor viral illnesses do not usually require a pause, and stopping and starting on your own can make the medicine less effective over time. Phoning the team before the next dose is the better habit, and they will say whether to hold it.

“Monitoring is mostly about the drug damaging my organs.” For biologics used alone, serious liver or kidney toxicity is unusual; the blood tests are largely about blood counts, infection and companion medicines. Methotrexate, if taken alongside, accounts for most of the liver monitoring.

“Once it works, the disease is gone.” Biologics control psoriatic arthritis; they do not remove the underlying tendency. Stopping is possible in some people in sustained remission, but it is a supervised decision, and flares after stopping are common enough that most teams prefer a gradual, monitored approach.

Questions to ask your care team before and during treatment

Clinic appointments move quickly, and the questions that matter most often surface on the drive home. Writing a few down beforehand changes that, and the list below is a starting point rather than a script. Pick the ones that apply.

Before the first dose, it helps to understand the reasoning: Which part of the immune system does this biologic block, and what does that mean for the infections I should watch for? Which of my screening results are back, and did any of them change the plan? Are there vaccines I should have before I start, and is there one I will no longer be able to have afterwards? If I need a live vaccine for travel, how far in advance do we need to arrange it?

About the ongoing schedule, ask: How often will I have blood tests in the first months, and how will that change if results stay normal? Who looks at the results, and how will I hear if something needs action? What should I do if I miss a dose because of an infection?

About daily life, the useful questions are practical: Should I call before a dose if I have a fever or am on antibiotics? What should I do about planned surgery or dental work? If I am thinking about pregnancy, which of my current medicines would need reviewing, and how early should we talk? How should I store and travel with the medicine?

And about the longer view: How will we judge whether this biologic is working, and when? What happens if it stops working? Is there a point at which stopping or spacing out doses would be considered?

Bring a note of any infections, however minor, since the last visit. It is the single most useful thing a patient can contribute to monitoring that no blood test captures.

When to call your doctor: red-flag signs on a biologic

Most of the time, monitoring is scheduled and unremarkable. The exceptions are symptoms that should prompt a call to the rheumatology team or, if severe, urgent care, without waiting for the next appointment.

Call the same day for a fever, shaking chills or feeling generally unwell in a way that is new, since infections can progress faster on immune-modifying treatment. Do the same for a cough lasting more than a couple of weeks, coughing up blood, drenching night sweats or unexplained weight loss, which are symptoms the CDC lists for tuberculosis disease and which a team will want to assess promptly. A painful, blistering rash on one side of the body may be shingles, and early antiviral treatment is most effective when started quickly.

Seek urgent care for breathing difficulty, chest pain, a severe or rapidly spreading skin infection, confusion, or signs of a serious allergic reaction during or after a dose such as swelling of the face or throat, widespread hives or dizziness. New weakness, numbness or vision changes should also be reported promptly, because of the rare association between TNF blockers and nerve inflammation.

Less dramatic but still worth a call: a mouth or throat infection that keeps returning, a wound or cut that is not healing, persistent diarrhea or abdominal pain, unusual bruising or bleeding, or yellowing of the skin or eyes. Each of these can point to a blood count, liver or gut issue that a routine test might not catch until the next scheduled draw.

If in doubt, phone. Rheumatology nurse lines exist precisely for this, and a call that turns out to be nothing is a far better outcome than an infection allowed to run for a week. Whether to hold a dose, repeat a test or change the plan is always the treating team’s decision, and they can only make it if they hear from you.

Frequently asked questions

What blood tests on biologics are done regularly for psoriatic arthritis?

The usual set is a full blood count, liver function tests, kidney tests and an inflammation marker such as C-reactive protein. The full blood count watches for falls in infection-fighting white cells, liver and kidney tests check for strain, and CRP helps track disease activity. The interval is set by the prescriber, is typically closer together in the early months, and is often driven more by a companion tablet such as methotrexate than by the biologic itself.

Why do I need a TB test before biologics if I feel completely well?

Because latent tuberculosis causes no symptoms yet can reactivate when TNF, a key defense signal, is blocked. The CDC describes latent infection as bacteria present in the body without illness, sometimes for decades. A skin test or IGRA blood test identifies it before treatment starts. A positive result usually leads to a chest X-ray and preventive treatment, after which the biologic can generally go ahead with the team’s agreement.

Can I have vaccines while on biologics?

Yes, and non-live vaccines are actively recommended. The CDC adult schedule includes yearly influenza vaccination, COVID-19 vaccination per current guidance, pneumococcal vaccination for people on immunosuppressive treatment, and the recombinant shingles vaccine for immunocompromised adults from age 19. Live vaccines, such as MMR, chickenpox, the nasal flu spray and yellow fever, are generally avoided once treatment has started, so any that are needed should be discussed before the first dose.

How high is the biologic infection risk in psoriatic arthritis?

Higher than without treatment, but mostly in the form of ordinary infections such as colds, urinary and skin infections. Mayo Clinic and Cleveland Clinic both identify infection as the main safety concern with biologics. Serious infections are uncommon and cluster in people who are older, have diabetes or lung disease, take steroid tablets, or have had serious infections before. Screening for tuberculosis and hepatitis B has made the rarer opportunistic infections much less frequent.

What happens if my hepatitis B test comes back positive before starting a biologic?

It usually changes the plan rather than ending it. A positive surface antigen means current infection, and a positive core antibody means past exposure that could reactivate. Either result typically prompts further blood tests, input from a liver specialist, and often antiviral medicine taken alongside the biologic with closer liver monitoring. The timing of the first dose is decided jointly by the rheumatology and liver teams.

Should I stop my biologic if I get a cold or need antibiotics?

Not on your own. Minor viral illnesses often do not need a pause, while an infection serious enough to need antibiotics frequently does, until it has cleared. The right step is to phone the rheumatology team before the next dose and let them decide. Repeatedly stopping and restarting without guidance can reduce how well the medicine works over time, so a quick call is the safer habit.

Do I need to pause my biologic before surgery or dental work?

Often yes for operations and major dental procedures such as extractions, because biologics can slow healing and raise infection risk. The length of any pause depends on the specific medicine and the type of surgery, and is agreed between the surgeon and rheumatologist. Routine dental cleaning and fillings usually need no change. Tell both teams about the biologic as early as possible so the timing can be planned.

How often will I see the rheumatology team once the biologic is established?

After the first months, reviews typically become less frequent, but the NHS describes ongoing regular monitoring for anyone on biological treatment. Each visit usually covers infections since the last appointment, joint and skin assessment, a check on blood results, and a yearly vaccine update. Blood test intervals are set by the prescriber and often lengthen when results stay stable. Any significant infection or planned operation should prompt contact between visits.

Is the shingles vaccine safe on biologics?

The recombinant shingles vaccine is non-live and can be given to people on biologics; the CDC recommends it for adults aged 50 and over and for immunocompromised adults from age 19. The older live shingles vaccine, where still available, is not suitable once treatment has started. Because shingles is more common on several immune-modifying medicines, many teams arrange the recombinant vaccine before or soon after starting.

Can I plan a pregnancy while on a biologic for psoriatic arthritis?

Many people do, but the plan needs reviewing early with the rheumatology team rather than stopping treatment unannounced. Some biologic classes have more reassuring pregnancy safety data than others, and uncontrolled arthritis during pregnancy carries its own risks. Companion medicines such as methotrexate must be stopped well before conception. Whether to continue, switch or pause the biologic is an individual decision made with the prescriber and, where relevant, an obstetric team.

References

• NHS: Psoriatic arthritis
• CDC: Testing for tuberculosis
• CDC: Adult immunization schedule by age
• MedlinePlus: Psoriatic arthritis

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.